Clinical Trials
99 trialsABBY
Abramson Cancer Center at Penn Medicine
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
PHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
THREAD
University of Utah
COAST
Medical University of South Carolina
LIMIT
Abramson Cancer Center at Penn Medicine
TAQE
VA Office of Research and Development
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
PaTcH
Cancer Trials Ireland
PALAVY
Abramson Cancer Center at Penn Medicine
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
HCQ in Resectable Localized Prostate Cancer
Dartmouth-Hitchcock Medical Center
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Pediatric Brain Tumor Consortium
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
RedHill Biopharma Limited
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
Abramson Cancer Center at Penn Medicine
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
Memorial Sloan Kettering Cancer Center
RIOM
West China Hospital
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer
Asan Medical Center
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
University of Kentucky
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
Affiliated Hospital of Nantong University
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
LY3214996 +/- HCQ in Pancreatic Cancer
Dana-Farber Cancer Institute
MEKiAUTO
Columbia University
OHSS
Aljazeera Hospital
UTAH
University of Utah
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Evaluation of Hydroxychloroquine to Prevent CIPN
University of Arizona
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
HITMAN-PC
St Vincent's Hospital, Sydney
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Cornerstone Pharmaceuticals
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin